Spreading of Alpha Synuclein from Glioblastoma Cells towards Astrocytes Correlates with Stem-like Properties.

cell clearing systems glioblastoma multiforme mammalian target of rapamycin stem cell markers synucleins trans-well co-culture model transmission electron microscopy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 Mar 2022
Historique:
received: 11 01 2022
revised: 01 03 2022
accepted: 08 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Evidence has been recently provided showing that, in baseline conditions, GBM cells feature high levels of α-syn which are way in excess compared with α-syn levels measured within control astrocytes. These findings are consistent along various techniques. In fact, they are replicated by using antibody-based protein detection, such as immuno-fluorescence, immuno-peroxidase, immunoblotting and ultrastructural stoichiometry as well as by measuring α-syn transcript levels at RT-PCR. The present manuscript further questions whether such a high amount of α-syn may be induced within astrocytes, which are co-cultured with GBM cells in a trans-well system. In astrocytes co-cultured with GBM cells, α-syn overexpression is documented. Such an increase is concomitant with increased expression of the stem cell marker nestin, along with GBM-like shifting in cell morphology. This concerns general cell morphology, subcellular compartments and profuse convolutions at the plasma membrane. Transmission electron microscopy (TEM) allows us to assess the authentic amount and sub-cellular compartmentalization of α-syn and nestin within baseline GBM cells and the amount, which is induced within co-cultured astrocytes, as well as the shifting of ultrastructure, which is reminiscent of GBM cells. These phenomena are mitigated by rapamycin administration, which reverts nestin- and α-syn-related overexpression and phenotypic shifting within co-cultured astrocytes towards baseline conditions of naïve astrocytes. The present study indicates that: (i) α-syn increases in astrocyte co-cultured with GBM cells; (ii) α-syn increases in astrocytes along with the stem cell marker nestin; (iii) α-syn increases along with a GBM-like shift of cell morphology; (iv) all these changes are replicated in different GBM cell lines and are reverted by the mTOR inhibitor rapamycin. The present findings indicate that α-syn does occur in high amount within GBM cells and may transmit to neighboring astrocytes as much as a stem cell phenotype. This suggests a mode of tumor progression for GBM cells, which may transform, rather than merely substitute, surrounding tissue; such a phenomenon is sensitive to mTOR inhibition.

Identifiants

pubmed: 35326570
pii: cancers14061417
doi: 10.3390/cancers14061417
pmc: PMC8946011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministero della Salute
ID : Ricerca corrente 2021

Références

Exp Mol Med. 2013 May 10;45:e22
pubmed: 23661100
Front Neuroanat. 2016 Jul 21;10:78
pubmed: 27493626
EMBO J. 2016 Oct 4;35(19):2120-2138
pubmed: 27550960
PLoS One. 2010 May 05;5(5):e10481
pubmed: 20463956
Front Neurosci. 2019 Jun 18;13:552
pubmed: 31275093
Biomol Ther (Seoul). 2013 May 30;21(3):222-8
pubmed: 24265868
Cancers (Basel). 2022 Mar 08;14(6):
pubmed: 35326535
Ann Oncol. 2017 Jul 1;28(7):1448-1456
pubmed: 28407030
Neuro Oncol. 2010 Aug;12(8):882-9
pubmed: 20472883
J Clin Neurosci. 2010 Dec;17(12):1515-9
pubmed: 20863706
Oncotarget. 2017 May 2;8(18):29574-29599
pubmed: 28418837
Neuropharmacology. 2014 Jul;82:132-42
pubmed: 23973294
Int J Mol Sci. 2020 May 05;21(9):
pubmed: 32380730
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5
pubmed: 19651612
Autophagy. 2018;14(1):98-119
pubmed: 29198173
PLoS One. 2011;6(5):e19622
pubmed: 21611169
J Microsc. 2000 Jul;199(Pt 1):1-36
pubmed: 10886526
Sci Rep. 2021 Mar 4;11(1):5267
pubmed: 33664298
Cancer Biol Ther. 2005 Sep;4(9):1018-29
pubmed: 16251803
Oncogene. 2007 Mar 22;26(13):1840-51
pubmed: 17001313
Curr Protein Pept Sci. 2018;19(6):598-611
pubmed: 29150919
Arch Ital Biol. 2012 Jun-Sep;150(2-3):194-217
pubmed: 23165879
Cancers (Basel). 2015 Aug 11;7(3):1554-85
pubmed: 26270676
J Biol Chem. 2010 Mar 19;285(12):9262-72
pubmed: 20071342
J Cell Sci. 2013 Jan 15;126(Pt 2):696-704
pubmed: 23203798
Front Neurosci. 2015 Nov 12;9:433
pubmed: 26617485
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832246
Cells. 2020 Jul 02;9(7):
pubmed: 32630739
Brain Res. 2010 Feb 8;1313:250-8
pubmed: 20004652
Methods Enzymol. 2009;453:273-86
pubmed: 19216911
Neoplasia. 2005 Apr;7(4):356-68
pubmed: 15967113
Brain Res. 2013 Feb 7;1495:37-51
pubmed: 23261661
J Biol Chem. 2013 Jan 18;288(3):1829-40
pubmed: 23184946
J Biol Chem. 2010 Oct 15;285(42):32486-93
pubmed: 20693280
Front Mol Neurosci. 2017 Jul 13;10:224
pubmed: 28751856
Neuroscience. 2021 Aug 1;468:186-198
pubmed: 34082066
Science. 2001 Feb 16;291(5507):1363-5
pubmed: 11233453
Cancer Res. 2012 Nov 15;72(22):5658-62
pubmed: 23139209
Acta Neuropathol. 2000 Feb;99(2):154-60
pubmed: 10672322
Mov Disord Clin Pract. 2017 Jun 01;4(5):724-732
pubmed: 30363411
Acta Neuropathol. 2003 Aug;106(2):167-75
pubmed: 12783249
Cancers (Basel). 2021 Jan 06;13(2):
pubmed: 33418999
Expert Opin Ther Targets. 2016;20(4):393-405
pubmed: 26878385
Hum Mol Genet. 2011 Sep 1;20(17):3401-14
pubmed: 21642386
Int J Cancer. 2011 Dec 1;129(11):2720-31
pubmed: 21384342
EMBO Rep. 2011 May;12(5):470-6
pubmed: 21460795
Onco Targets Ther. 2020 Sep 11;13:9085-9099
pubmed: 32982297
Science. 2010 Sep 24;329(5999):1663-7
pubmed: 20798282
Cell Death Dis. 2018 Jul 9;9(7):757
pubmed: 29988147
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5308-17
pubmed: 26324905
Biomedicines. 2020 Oct 14;8(10):
pubmed: 33066407
Exp Neurobiol. 2014 Dec;23(4):292-313
pubmed: 25548530
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561595
Histol Histopathol. 2017 May;32(5):413-431
pubmed: 27775777
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3581-6
pubmed: 18299565
J Histochem Cytochem. 2004 Aug;52(8):991-1000
pubmed: 15258174
Mov Disord. 2021 Jul;36(7):1489-1498
pubmed: 34021920
Science. 2014 Oct 10;346(6206):237-41
pubmed: 25301628
Nat Rev Neurol. 2010 Dec;6(12):702-6
pubmed: 21045796
Autophagy. 2021 Jan;17(1):1-382
pubmed: 33634751
Int J Mol Sci. 2021 May 08;22(9):
pubmed: 34066733
Brain. 2017 Apr 1;140(4):878-886
pubmed: 27585855
Nat Rev Mol Cell Biol. 2010 Apr;11(4):301-7
pubmed: 20308987
Histochem Cell Biol. 2008 Aug;130(2):299-313
pubmed: 18553098
Hum Mol Genet. 2019 Jul 15;28(14):2283-2294
pubmed: 31267130
Neurobiol Aging. 2003 Sep;24(5):687-96
pubmed: 12885576
Biochim Biophys Acta. 2012 Feb;1818(2):162-71
pubmed: 21819966
Brain Res. 2007 Jan 19;1129(1):174-90
pubmed: 17157274
J Clin Oncol. 2004 May 15;22(10):1926-33
pubmed: 15143086
J Adv Res. 2020 Jan 22;23:37-45
pubmed: 32071790
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Biol Chem. 2003 Jul 4;278(27):25009-13
pubmed: 12719433
J Histochem Cytochem. 1983 Jan;31(1):101-9
pubmed: 6187796
J Parkinsons Dis. 2015;5(4):699-713
pubmed: 26407041
Traffic. 2009 Feb;10(2):218-34
pubmed: 18980610
Cancer. 2000 May 1;88(9):2154-63
pubmed: 10813729
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
J Neurosci. 2012 Jun 6;32(23):7926-40
pubmed: 22674268
J Neurooncol. 2011 Jul;103(3):453-8
pubmed: 20878445
Micron. 2004;35(4):287-96
pubmed: 15003616

Auteurs

Larisa Ryskalin (L)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

Francesca Biagioni (F)

Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy.

Gabriele Morucci (G)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

Carla L Busceti (CL)

Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy.

Alessandro Frati (A)

Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy.
Neurosurgery Division, Human Neurosciences Department, Sapienza University, 00135 Roma, Italy.

Stefano Puglisi-Allegra (S)

Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy.

Michela Ferrucci (M)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy.

Francesco Fornai (F)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy.

Classifications MeSH